To further investigate the role of PTPRM in the progression of EOC, the relationship between the expression of PTPRM and clinicopathological parameters—such as patient's age, clinical stage, pathological type, age of menarche, age of menostasis, number of pregnancies, family history of malignancy, presence of medical comorbidities, serum tumor marker levels (cancer antigen [CA]125, CA19-9, human epididymis protein 4 [HE4]), presence of ascites, tumor diameter, bilateral mass or not, lymph node metastasis, and disease recurrence—were analyzed separately. This evidence concerns the gene PTPRM and neoplasm.